123 related articles for article (PubMed ID: 22006274)
21. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.
Dabaja BS; Vanderplas AM; Crosby-Thompson AL; Abel GA; Czuczman MS; Friedberg JW; Gordon LI; Kaminski M; Niland J; Millenson M; Nademanee AP; Zelenetz A; LaCasce AS; Rodriguez MA
Cancer; 2015 Apr; 121(7):1032-9. PubMed ID: 25492236
[TBL] [Abstract][Full Text] [Related]
22. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?
Siegal T; Goldschmidt N
Blood Rev; 2012 May; 26(3):97-106. PubMed ID: 22244544
[TBL] [Abstract][Full Text] [Related]
23. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).
Peñalver FJ; Sancho JM; de la Fuente A; Olave MT; Martín A; Panizo C; Pérez E; Salar A; Orfao A;
Haematologica; 2017 Feb; 102(2):235-245. PubMed ID: 27846613
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
Ghose A; Kundu R; Latif T
Crit Rev Oncol Hematol; 2014 Sep; 91(3):292-303. PubMed ID: 24698003
[TBL] [Abstract][Full Text] [Related]
25. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.
Fletcher CD; Kahl BS
Leuk Lymphoma; 2014 Oct; 55(10):2228-40. PubMed ID: 24286262
[TBL] [Abstract][Full Text] [Related]
26. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
27. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
Klanova M; Sehn LH; Bence-Bruckler I; Cavallo F; Jin J; Martelli M; Stewart D; Vitolo U; Zaja F; Zhang Q; Mattiello F; Sellam G; Punnoose EA; Szafer-Glusman E; Bolen CR; Oestergaard MZ; Fingerle-Rowson GR; Nielsen T; Trneny M
Blood; 2019 Feb; 133(9):919-926. PubMed ID: 30617197
[TBL] [Abstract][Full Text] [Related]
28. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Gleeson M; Counsell N; Cunningham D; Chadwick N; Lawrie A; Hawkes EA; McMillan A; Ardeshna KM; Jack A; Smith P; Mouncey P; Pocock C; Radford JA; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Ann Oncol; 2017 Oct; 28(10):2511-2516. PubMed ID: 28961838
[TBL] [Abstract][Full Text] [Related]
29. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
30. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.
Savage KJ; Slack GW; Mottok A; Sehn LH; Villa D; Kansara R; Kridel R; Steidl C; Ennishi D; Tan KL; Ben-Neriah S; Johnson NA; Connors JM; Farinha P; Scott DW; Gascoyne RD
Blood; 2016 May; 127(18):2182-8. PubMed ID: 26834242
[TBL] [Abstract][Full Text] [Related]
31. Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
Oki Y; Noorani M; Lin P; Davis RE; Neelapu SS; Ma L; Ahmed M; Rodriguez MA; Hagemeister FB; Fowler N; Wang M; Fanale MA; Nastoupil L; Samaniego F; Lee HJ; Dabaja BS; Pinnix CC; Medeiros LJ; Nieto Y; Khouri I; Kwak LW; Turturro F; Romaguera JE; Fayad LE; Westin JR
Br J Haematol; 2014 Sep; 166(6):891-901. PubMed ID: 24943107
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
Eyre TA; Djebbari F; Kirkwood AA; Collins GP
Haematologica; 2020 Jul; 105(7):1914-1924. PubMed ID: 31488560
[TBL] [Abstract][Full Text] [Related]
33. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA; Kirkwood AA; Wolf J; Hildyard C; Mercer C; Plaschkes H; Griffith J; Fields P; Gunawan A; Oliver R; Booth S; Martinez-Calle N; McMillan A; Bishton M; Fox CP; Collins GP; Hatton CSR
Br J Haematol; 2019 Oct; 187(2):185-194. PubMed ID: 31222719
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive review of the role of bone marrow biopsy and PET-CT in the evaluation of bone marrow involvement in adults newly diagnosed with DLBCL.
Alyamany R; El Fakih R; Alnughmush A; Albabtain A; Kharfan-Dabaja MA; Aljurf M
Front Oncol; 2024; 14():1301979. PubMed ID: 38577334
[TBL] [Abstract][Full Text] [Related]
35. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
[TBL] [Abstract][Full Text] [Related]
36. Prevention and management of secondary central nervous system lymphoma.
Bobillo S; Khwaja J; Ferreri AJM; Cwynarski K
Haematologica; 2023 Mar; 108(3):673-689. PubMed ID: 36384246
[TBL] [Abstract][Full Text] [Related]
37. SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.
Simard J; Roschewski M
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):709-717. PubMed ID: 35787364
[TBL] [Abstract][Full Text] [Related]
38. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Bobillo S; Joffe E; Sermer D; Mondello P; Ghione P; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Batlevi CL; Moskowitz A; Noy A; Owens CN; Palomba ML; Straus D; von Keudell G; Dogan A; Zelenetz AD; Seshan VE; Younes A
Blood Cancer J; 2021 Jun; 11(6):113. PubMed ID: 34135307
[TBL] [Abstract][Full Text] [Related]
39. Real-World Data (RWD) on the 3-Year Follow-Up Outcomes of Different CNS Prophylaxis Strategies Across CNS-IPI Risk Groups in Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma.
Faqah A; Asif S; Goksu SY; Sheikh HS
JCO Glob Oncol; 2021 Apr; 7():486-494. PubMed ID: 33835825
[TBL] [Abstract][Full Text] [Related]
40. Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.
Kuitunen H; Kaprio E; Karihtala P; Makkonen V; Kauppila S; Haapasaari KM; Kuusisto M; Jantunen E; Turpeenniemi-Hujanen T; Kuittinen O
Ann Hematol; 2020 Aug; 99(8):1823-1831. PubMed ID: 32577843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
